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Hepatopancreatobiliary (HPB) emergencies include an ample range of conditions with overlapping clinical presentations
and diverse therapeutic options. The most common etiologies are related to cholelithiasis (acute cholecystitis, pancreatitis,
and cholangitis) and non-traumatic injuries (common bile duct or duodenal). Although the true incidence of HPB
emergencies is difficult to determine due to selection and reporting biases, a population-based report showed a
decline in the global incidence of all severe complications of cholelithiasis, primarily based on a reduction in acute
cholecystitis. Even though patients may present with overlapping symptoms, treatment options can be varied. The
treatment of these conditions continues to evolve and patients may require endoscopic, surgical, and/or percutaneous
techniques. Thus, it is essential that a multidisciplinary team of HPB surgeons, interventional gastroenterologists
and radiologists are available on an as needed basis to the Acute Care Surgeon. This focused manuscript is a
contemporary review of the literature surrounding HPB emergencies in the context of the acute care surgeon.
The main aim of this review is to offer an update of the diagnosis and management of HPB issues in the acute
care setting to improve the care of patients with potential HPB emergencies.
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Hepatopancreatobiliary (HPB) emergencies for the Acute
Care Surgeon (ACS) include a wide range of diseases
with variable clinical presentations and diverse thera-
peutic options. Fortunately most acute presentations can
be classified as consequences of either inflammatory
(gallstones, pancreatitis, cholangitis) or injury (common
bile duct, duodenum) etiologies [1-3].
It is estimated that 1% to 4% of asymptomatic or
mildly symptomatic patients will develop an acute com-
plication of cholelithiasis [4]. These include cholecystitis,
cholangitis and pancreatitis. Acute cholecystitis is the
most frequent of these diseases [1,5]. Unfortunately de-
termining the true incidence of HPB emergencies re-
mains difficult due to selection and reporting biases. A
recent population-based study showed a decline in the* Correspondence: ball.chad@gmail.com
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iasis [6]. This was primarily based on a reduction in
acute cholecystitis due to the wide spread adoption of
laparoscopic cholecystectomy. Conversely, the incidence
of acute biliary pancreatitis and cholangitis has increased
during the same interval [6,7].
Although many of these HPB emergencies present
with overlapping symptoms, treatment options can be
diverse [8]. They may require endoscopic, surgical, and/
or percutaneous techniques. As a result, it is essential
that a multidisciplinary team of HPB surgeons, interven-
tional gastroenterologists and radiologists are available
on an as needed basis to the Acute Care Surgeon. Simi-
larly, those patients who are not able to receive complete
or gold standard therapy should be referred elsewhere
without delay.
The aim of this review is to update the management of
patients diagnosed with non-trauma HPB emergencies
in the context of the ACS service.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Butte et al. World Journal of Emergency Surgery  (2015) 10:13 Page 2 of 10General assessment
Similar to trauma, the initial evaluation of patients pre-
senting with a HPB emergency should include simul-
taneous diagnosis and therapy. This concurrent rapid
assessment and treatment is particularly important for
patients who present with sepsis. A detailed clinical his-
tory of the acute event, including a focused past medical
history (i.e. history of gallstones, pancreatitis, duodenal
ulcer/NSAID use, and/or cancer) and complete physical
examination are crucial. These details may suggest the
likely diagnosis, determine the severity of the acute event,
and guide both immediate and subsequent treatments. It
is important to note that most patients present with an in-
flammatory and/or septic complication of a previously
known disease, as opposed to a completely de novo eti-
ology. Thus, patients presenting with acute cholecystitis
or another complication of gallstones typically have a
known history of symptomatic cholelithiasis. By contrast,
patients suffering from pancreatic diseases generally de-
velop symptoms after an acute new event.
The first step in caring for these patients requires a
direct assessment of the severity of the acute event itself.
Septic shock and acute bleeding represent the most
common causes of hemodynamic compromise and must
be addressed immediately. These methodologies include
intravenous fluid resuscitation, early initiation of anti-
microbial therapy, and blood product transfusion as
needed. It is important to highlight that these patients
often present with nausea and vomiting, dehydration,
acute kidney injury, electrolyte imbalances, anemia, and/
or coagulation abnormalities. A recent systematic review
of 78 trials showed that resuscitation with colloids does
not reduce the risk of death, nor improve survival [9]. It
is also more expensive than resuscitation with crystal-
loids [9]. Another prospective randomized trial showed
that patients with severe sepsis undergoing resuscitation
with Ringer’s solution had a decreased 90-day mortality
and renal-replacement therapy rate when they were
compared with patients who received Hydroxyethyl
starch 130/0.42 [10]. Thus, it is recommended that pa-
tients with HPB emergencies undergo active and early
resuscitation with crystalloids [9].
Numerous scoring models have been created to deter-
mine the severity of the acute HPB event [11]. These in-
clude, but are not limited to, the acute and physiology
and chronic health evaluation (APACHE) III and IV, the
simplified acute physiology score (SAPS) 3, and the mor-
tality probability model (MPM) III. These scores were
recently compared in 2596 patients with the aim of de-
termining their value in predicting mortality [12]. The
discriminatory performances of APACHE III and IV
were similar, but also superior to both SAPS 3 and
MPM III scores. Despite superior calibration and dis-
crimination amongst surgical patients in particular, theAPACHE III or IV assessments are not overly simple to
determine in the initial resuscitation phase. It is also
clearly important to obtain focused liver and pancreatic
function, as well as liver enzyme tests during the evalu-
ation to guide resuscitation and narrow the differential
diagnosis.
Once effectively resuscitated, patients should undergo
diagnostic imaging tests to rapidly determine the etiology
and guide further treatment. The type of study required
will depend on patient status and clinical suspicion. These
may include bedside and/or formal abdominal ultrasound
(US), hepatobiliary scintigraphy (HIDA), computed tom-
ography (CT), endoscopic retrograde cholangiography
(ERCP), magnetic resonance (MR) cholangiography and/
or endoscopic ultrasound (EUS).
Biliary inflammatory diseases
Acute calculous cholecystitis (AC)
Acute inflammation of the gallbladder is a frequent com-
plication of cholelithiasis, and affects up to 20% of pa-
tients with recurrent symptomatic gallstones [4]. Despite
the history that most patients provide (previous episodes
of transient colic pain in their right upper quadrant),
acute presentations to a health care facility are typically
longer and associated with additional symptoms (nausea
or vomiting after ingesting high fat foods). Obstruction
of the cystic duct by a gallstone or sludge produces dila-
tion of the gallbladder and increases its internal pressure
[8]. Subsequent biliary stasis and the proliferation of mi-
croorganisms is typical. If the obstruction persists, ven-
ous outflow decreases, with dilatation of capillaries and
lymphatics resulting in gallbladder wall edema and
thickening [4]. Eventually the gallbladder develops areas
of hemorrhage and necrosis due to vascular occlusion.
Imaging and exploration may reveal both fluid and air
within the gallbladder wall. If the ischemia and necrosis
is located within the posterior wall (i.e. apposed to the
liver), a pericholecystic abscess eroding into the liver
commonly occurs. It is also important to note that spe-
cific complications such as perforation, biliary periton-
itis, pericholecystic abscess and biliary fistula (between
the gallbladder and duodenum, colon, or stomach) may
alter the clinical presentation and increase morbidity
and mortality of the disease. Bouveret’s syndrome, gas-
tric outlet obstruction, biliary ileus and gallstone-related
small bowel obstruction are uncommon complications
that should be identified.
The initial assessment of these patients includes 2
dominant objectives: [1] confirming the diagnosis and
[2] establishing its severity. Despite a wide array of op-
tions (US, HIDA, CT, MR), the revised Tokyo consensus
guidelines represent the best parameters for directing
diagnosis and treatment [5,13]. Based on diagnostic sen-
sitivities of 90% to 95%, abdominal US remains the
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formed by the ACS within the emergency department it-
self, it is also cost saving and rapid. Identification of
gallbladder wall thickening (>5 mm), an obstructing gall-
stone in the gallbladder neck, pericholecystic fluid, US
Murphy’s sign and/or dilation and thickening of the
common bile duct (CBD) are important signs that con-
tribute to defining the diagnosis. Unfortunately CT im-
aging is far less specific and frequent in confirming this
diagnosis. After confirmation however, the disease
should be classified according its severity (grade I = mild,
II = moderate, III = severe). While grade II refers to the
presence of systemic signs of inflammation, grade III
cholecystitis includes dysfunction of at least one organ/
system [13] (Table 1).
The treatment of patients with AC should include
general medical therapy (nil per mouth (NPO), intra-
venous fluids, antibiotics and analgesia) followed by ur-
gent cholecystectomy. The 2 dominant surgical issues
include the type (open vs. laparoscopic) and timing
(early vs. delayed) of the procedure. Two small pro-
spective randomized trials compared open with laparo-
scopic surgery for acute cholecystitis. The first study
showed that open cholecystectomy had a significantly
higher number of postoperative complications, as well
as a longer postoperative hospital stay (6 vs. 4 days).
No mortality or bile duct injuries were observed in this
study [14]. A more recent trial included 70 patients and
did not show any significant difference in the rate of
postoperative complications [15]. The laparoscopic
group had a significantly longer median operating timeTable 1 “Severity assessment criteria for acute cholecystitis”
Grade Definition
I (mild) Acute cholecystitis does not meet the cri
It can also be defined as acute cholecysti
changes in the gallbladder, making chole
II (moderate) Acute cholecystitis is associated with any
1. Elevated white blood cell count (>18,0
2. Palpable tender mass in the right uppe
3. Duration of complaints > 72 hours
4. Marked local inflammation (gangrenou
emphysematous cholecystitis).
III (severe) “Grade III” (severe) acute cholecystitis is a
1. Cardiovascular dysfunction defined as h
any dose of norepinephrine
2. Neurological dysfunction defined as de
3. Respiratory dysfunction defined as a Pa
4. Renal dysfunction defined as oliguria, c
5. Hepatic dysfunction defined as PT-INR
6. Hematological dysfunction defined as p
From “Yokoe M, et al. [1] (with permission).(90 vs. 80 minutes) and shorter median postoperative
stay. The timing of cholecystectomy has also been eval-
uated in prospective randomized trials. Numerous
small studies have observed that patients undergoing
early cholecystectomy have a shorter hospital stay,
without any other significant differences [16-22]. A re-
cent meta-analysis that included 451 patients from 5
trials comparing early (less than 7 days from the onset
of symptoms) with delayed (more than six weeks after
the index admission) cholecystectomy revealed no sta-
tistically significant difference between the groups with
regard to bile duct injuries (BDI) or conversion to open
surgery [23]. The hospital stay was 3 days shorter in the
early group however. Importantly, 40 (17.5%) patients
in the delayed group required an emergency cholecyst-
ectomy during their waiting period for non-resolving
or recurrent AC. It is also evident from large popula-
tion based studies that the rate of BDI increases with
higher grades of cholecystitis [4]. The most recent
prospective multicenter trial comparing the optimal
timing for cholecystectomy (early, during the first
24 hours vs. delayed) in patients with acute cholecyst-
itis confirmed that early cholecystectomy was associ-
ated with significantly lower morbidity (11.8 vs.
34.4%). Although conversion to open surgery, nor
mortality differed between groups, the mean length of
hospital stay (5.4 vs. 10 days) and hospital costs were
significantly lower in the group treated with early
cholecystectomy [24]. Taken together, these results
suggest that early laparoscopic surgery should be con-
sidered the treatment of choice.teria of “Grade III” or “Grade II”
tis in a healthy patient with no organ dysfunction and mild inflammatory
cystectomy a safe and low-risk operative procedure.
one of the following conditions:
00/mm3)
r abdominal quadrant
s cholecystitis, pericholecystic abscess, hepatic abscess, biliary peritonitis,
ssociated with dysfunction of any one of the following organs/systems
ypotension requiring treatment with dopamine≥ 5 μg/kg per min, or
creased level of consciousness
O2/FiO2 ratio < 300
reatinine > 2.0 mg/dl
> 1.5
latelet count < 100,000/mm3
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cystitis should undergo early laparoscopic cholecystec-
tomy, with awareness of the extent of the gallbladder’s
inflammation (i.e. defining biliary anatomy to prevent
BDI). More specifically, the ACS surgeon must be particu-
larly wary of the inflamed gallbladder that is contracted
into the liver bed because the anatomy in this scenario
represents the most common etiology for BDI. Patients
with grade III acute cholecystitis should undergo chole-
cystectomy once organ dysfunction is reversed [25]. In the
setting of persistent organ failure or poor surgical candi-
dacy, antimicrobial therapy and concurrent percutaneous
cholecystostomy should be performed [26].
The role for antibiotic prophylaxis prior to elective
laparoscopic cholecystectomy has been studied in pro-
spective randomized trials. Unfortunately the evidence
remains insufficient to either support or refute their use
in an attempt to reduce surgical site and global infec-
tions. This question has not been evaluated for patients
undergoing urgent cholecystectomy for acute cholecyst-
itis in any trials however. As a result, consensus guide-
lines recommend that antibiotic therapy should be
started if infection is suspected on the basis of clinical,
laboratory, and/or radiographic findings [27]. Treatment
should include coverage for the Enterobacteriaceae fam-
ily (i.e. second generation cephalosporin, or a combin-
ation of a quinolone and metronidazole) [4]. Treatment
of enterococci is debated. Elderly patients and those with
diabetes mellitus or immunosuppressive disorders should
receive antibiotics even when infection has not been con-
firmed. Obtaining aerobic and anaerobic cultures from the
bile during surgery is also recommended to guide treat-
ment in complex cases [4].
The role of routine intraoperative cholangiography has
been evaluated in patients undergoing elective cholecyst-
ectomy [28]. Eight randomized trials (1715 patients)
were analyzed in a recent systematic review without
showing any clear evidence to support its routine use
[29]. When this is combined with the fact that there are
no randomized studies in patients undergoing cholecyst-
ectomy for acute cholecystitis, intraoperative cholangi-
ography should be performed selectively in the setting of
concerning pre- and/or intra-operative findings.
AC in specific scenarios (jaundice, acalculous acute
cholecystitis, pregnancy)
The presence of jaundice should be evaluated with caution
because it reflects a wide spectrum of potentially benign
and malignant conditions. These include, but are not lim-
ited to, CBD obstruction from external compression
(cholangiocarcinoma, periampullary cancers, gallbladder
cancer), choledocholithiasis, and liver failure (e.g. second-
ary to sepsis). Although US continues to be the diagnostic
gold standard for detecting choledocholithiasis (especiallywithin the distal CBD), MR cholangiography (MRC) may
also be useful to define the etiology [30]. The dominant
goals in the treatment of patients with choledocholithiasis
are three-fold: [1] treat concurrent sepsis, [2] evacuate the
CBD, and [3] prevent future recurrences. Although the
order of the latter 2 goals is debated on the basis of
length of stay, safety and economics, it is clear that
ERCP and laparoscopic cholecystectomy represent the
2 dominant therapies [31,32]. Laparoscopic CBD ex-
ploration (transcystic or transductal) is also a viable op-
tion and has the added benefit of being performed as a
single procedure [33,34].
Acalculous cholecystitis is an uncommon and serious
presentation observed in 5% to 10% of patients with bil-
iary emergencies [35]. It is typically associated with crit-
ical illness, immunosuppressive conditions, uncommon
pathogens (anaerobes), and/or sepsis [35]. On a global
basis, patients with acquired immunodeficiency syn-
drome (AIDS) continue to represent the most common
immunosuppressive cases and are younger, present with
elevations in their alkaline phosphatase and serum bili-
rubin, and may have cytomegalovirus and cryptosporid-
ium associated infections [36]. Other rare causes of
acalculous cholecystitis are chemical cholecystitis after
hepatic artery infusion, antibiotic-related cholecystitis,
and parasites (ascaris). Since patients with acalculous
cholecystitis often present with organ dysfunction and
are poor surgical candidates, medical treatment is often
the therapy of choice, with surgery performed in selected
cases (i.e. if cholecystostomy is ineffective) [35].
Pregnant patients carry a higher risk of developing both
gallstones and acute cholecystitis than non-pregnant pa-
tients [37,38]. Complications of gallstones remain the sec-
ond most common cause of surgery during pregnancy
[39]. Despite this epidemiology, surgery should be avoided
during the first (i.e. abortion) and third (i.e. premature
delivery) trimesters if possible. Most symptomatic pa-
tients treated with nonoperative therapy present with
recurrence of their symptoms however. Of this cohort,
approximately 30% eventually require surgery during
their pregnancy [40].
Acute cholangitis
Acute cholangitis is defined as acute inflammation and
infection of the biliary tree. This is most commonly a
consequence of biliary obstruction followed by bacterial
overgrowth within bile [41]. The dominant cause of
acute cholangitis is choledocholithiasis, followed by be-
nign biliary stenosis and cancer. Interestingly, a recent
report that included 794 patients did not show a signifi-
cant difference between the incidence of gallstones
(50.6%) and malignancies (49.4%) as the main source of
obstruction [8,42]. This likely reflects an aging populous.
Regardless of the cause or site, obstruction of the biliary
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an increase in the number of microorganisms followed
by a rise in the intraductal pressure of the bile duct. This
increases ductal permeability and facilitates translocation
of bacteria and their products into the vascular system.
This process is highly dependent upon contamination of
normally aseptic bile. It is also supported by data that re-
ports 16% of patients undergoing a non-biliary oper-
ation, 72% with acute cholangitis, 44% with chronic
cholangitis, 50% with acute biliary obstruction, and 90%
of patients with choledocholithiasis and jaundice have
positive biliary cultures [8].
Patients with cholangitis may present with a wide var-
iety of symptoms from nonspecific findings to severe in-
fection and fatal septic shock. Morbidity and mortality
are minimized only via early diagnosis and treatment.
Given that Charcot’s triad (jaundice, fever and right
upper quadrant peritonitis) has a high specificity (>90%),
but is observed in only 18.5% of patients, a high level of
suspicion for the diagnosis is essential [3].
This reality is reinforced by the Tokyo guidelines that
summarize the diagnosis must include at least [1] signs of
systemic inflammation (i.e. fever), [2] cholestasis, and [3]
specific findings on imaging [3,5] (Table 2). Current rec-
ommendations also grade the severity of cholangitis (I
(mild = diagnosis of exclusion), II (moderate = systemic in-
flammation without organ dysfunction), or III (severe =
concurrent dysfunction of at least 1 organ system)).Table 2 “Severity assessment criteria for acute cholangitis”
Grade Definition
I (mild) Acute cholangitis does not meet the criteria o
Patients should have early diagnosis, biliary d
It is recommended that patients with acute c
supportive care and antimicrobial therapy) un
II (moderate) Acute cholangitis associated with any two of
1. Abnormal white blood cell count (>12,000/
2. High fever (≥39°C)
3. Age (≥75 years old)
4. Hyperbilirubinemia (total bilirubin ≥ 5 mg/d
5. Hypoalbuminemia (< STD × 0.7)
III (severe) Acute cholangitis associated with the onset o
1. Cardiovascular dysfunction defined as hypo
dose of norepinephrine
2. Neurological dysfunction defined as decrea
3. Respiratory dysfunction defined as a PaO2/
4. Renal dysfunction defined as oliguria, creat
5. Hepatic dysfunction defined as PT-INR > 1.5
6. Hematological dysfunction defined as plate
STD lower limit of normal value.
Kiriyama S, et al. [5] (with permission).Despite this grading system, most patients (54%) present
with grade I disease (only 11% develop grade III).
The treatment of acute cholangitis has shown dramatic
improvement over the past decade with a current mor-
tality of less than 30% (i.e. sepsis leading to multiorgan
failure) [3]. Patients should receive general medical ther-
apy including NPO, intravenous fluids, antibiotics, and
analgesia [27]. In addition to critical care, various tech-
niques for biliary decompression are also mandated [43].
Approaches include endoscopic, percutaneous and/or
operative approaches based on the etiology of the chol-
angitis and patient physiology [44,45]. Medical treatment
may be sufficient in selected cases of grade I, but biliary
drainage should be considered for all non-responders
[46]. This scenario often incorporates postoperative pa-
tients. Patients with grade II disease require early endo-
scopic, percutaneous or emergent operative (T-tube)
biliary drainage. These drainage procedures may be de-
finitive for patients with gallstone-associated cholangitis
[46]. Although it remains controversial if patients with
cancer should undergo a definitive resection concurrent
to their emergent decompression procedure, this is gen-
erally not recommended due to a lack of complete sta-
ging, higher postoperative complications, and known
hospital volume-outcome relationships. Patients with
cancer should be stabilized, undergo emergency drain-
age, and be referred for definitive treatment to a high
volume HPB center. In the most critically ill patients, af “Grade II or III”, representing acute cholangitis at initial diagnosis. Notes
rainage and/or treatment for etiology, and antimicrobial administration.
holangitis who do not respond to the initial medical treatment (general




f dysfunction in at least one of any of the following organs/systems:
tension requiring treatment with dopamine ≥ 5 μg/kg per min, or any
sed level of consciousness
FiO2 ratio < 300
inine > 2.0 mg/dl
let count < 100,000/mm3
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physicians and sometimes HPB surgeons should partici-
pate with the ACS in the management of these patients.
The type of biliary drainage selected by the surgeon is
particularly important. Patients with hilar cholangiocar-
cinoma most often benefit from a percutaneous tech-
nique (percutaneous transhepatic catheter (PTC) as
opposed to endoscopic). ERCP-based attempts at drain-
age of hilar cholangiocarcinoma are notorious for failing
to achieve adequate drainage within the proximal liver
and subsequently often develop significant cholangitis
due to instrumentation of the biliary system during this
attempt. These patients must also receive high fidelity
cholangiographic information either prior to (MRCP), or
concurrent to the insertion of the PTC (i.e. via the PTC
itself ) to define resectability and reconstruction options.
Patients with any periampullary malignancy should
undergo ERCP-based stenting as the initial choice.
Patients with grade III cholangitis require admission to
the intensive care unit for physiologic support, in
addition to general medical treatment [46]. Urgent endo-
scopic, percutaneous or surgical biliary drainage must
also be performed. Considering that these patients are
often physiologically unstable, the most rapid and least
invasive procedure should be selected (operative inter-
vention should be the last resort given the high associ-
ated mortality). Once the cholangitis has resolved,
definitive treatment of the etiology (i.e. laparoscopic
cholecystectomy for cholelithiasis, resection for cancer)
is indicated.
Severe acute pancreatitis (SAP)
Acute pancreatitis is a common disease that affects ap-
proximately 200,000 people per year in the United States
[47]. It was classically defined by the Atlanta guidelines
in 1992 as “an acute inflammatory process of the pan-
creas with variable involvement of regional or distant
organ/systems and high levels of pancreatic enzyme in
blood and/or urine” [48]. Although the differential diag-
nosis for causes of pancreatitis is broad, choledocholithi-
asis remains the most common [49]. SAP is observed in
approximately 20% of patients, and depends on the pres-
ence of organ failure and local complications (necrosis,
pseudocyst, and walled off pancreatic necrosis). The
dominant definition of SAP includes subsets of patients
with organ failure, necrotizing pancreatitis without
organ failure, and infected pancreatic necrosis with
organ failure [2,50]. Given that this definition considers
groups with vastly different prognoses, it has been re-
cently revised by a group of experts [50]. It is now based
on local and systemic determinants of severity. The local
determinants include pancreatic and/or peripancreatic
necrosis (P-PN). These 2 entities have been included to-
gether and represent all non-viable tissue (solid orsemisolid) that does not have a radiologically defined
wall. Thus, pancreatic necrosis is defined as any area of
non-enhancement on contrast-enhanced CT and peri-
pancreatic necrosis includes every heterogeneous peripan-
creatic collection on CT until proven otherwise. P-PN
may be considered infected when gas bubbles are ob-
served on CT scan, or when a culture obtained by percu-
taneous or surgical techniques is positive [50]. It should
be noted that the routine use of broad-spectrum prophy-
lactic antibiotics has altered the bacteriology of secondary
pancreatic infection in severe acute pancreatitis, from pre-
dominantly gram-negative to gram-positive bacteria with-
out changing the rate of beta-lactam resistance or
fungal super-infection [51]. Systemic determinants refer
to distant organ failure, which is defined for 3 systems
on the basis of the worst measurement in a 24-hour
period or when the creatinine is ≥ 2 mg/dl, PaO2/FiO2
is ≤ 300, or inotropic agents are required. Transient fail-
ure is defined as failure of the same organ/system for
less than 48 hours, while persistent failure implies more
than 48 hours. Based on this new consensus grading,
acute pancreatitis is described as [1] mild (P-PN and
organ failure are absent), [2] moderate (sterile P-PN
and/or transient organ failure), [3] severe (either in-
fected P-PN or persistent organ failure), or [4] critical
(infected P-PN with persistent organ failure) [50].
Despite guideline recommendations, every patient
should receive personalized treatment based on the se-
verity of their disease and the direction of a multidiscip-
linary team. The surgical treatment of patients with SAP
has evolved dramatically and includes open, laparo-
scopic, radiologic, and endoscopic techniques of de-
bridement and drainage [52,53]. These approaches may
be used alone, or in combination [54]. Despite this long
list of potential techniques to remove necrotic tissue,
the more dominant issue for the ACS surgeon is one of
timing. It is clear that early debridement increases
blood loss, morbidity, the number of operative inter-
ventions, and mortality across all groups of patients
with SAP [55]. More specifically, almost every patient
should be physiologically supported without major
intervention until the 28-day mark. Patients with SAP fol-
low a predictable pattern of early SIRS and potentially
multi-organ failure as a result. This interval observation is
often misinterpreted as sepsis requiring treatment with
antimicrobial therapy. Within the first 7 to 10 days, very
few of these patients have infected necrosis (and therefore
require antibiotics). The most common exceptions to this
rule of delayed (28-day) intervention remains patients
with concurrent ischemia of the bowel or gallbladder [56].
As a result, it is ischemia of these 2 organs that must be
ruled out if a critically ill patient decompensates, as op-
posed to focusing on the status of the pancreas itself (in-
fected or not).
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necrosum is mature, operative therapies may include
both minimally invasive (laparoscopic cystgastrostomies
and debridements, utilization of percutaneous drains as
access guides for rigid scope debridement, step-up pro-
cedures, endoscopic transmural debridements) and
open (transperitoneal, retroperitoneal-flank) approaches
[47,57-59]. The best choice amongst these options is
based on patient anatomy and the specific location(s) of
the necrosum.
The recent publication popularity in percutaneous
techniques as treatment for pancreatic necrosis de-
serves specific mention. CT-guided drainage followed
by repeated irrigation procedures in the context of ever
increasingly larger drains placed by involved and com-
mitted radiologists may improve the clinical course in
up to 75% of patients. It has also been shown to resolve
the necrotic collection in 45% of cases. This technique
is incredibly labor intensive however, and therefore not
available in most centers.
In addition to the role of surgery, significant literature
exists with reference to the role of prophylactic antibi-
otics, early ERCP decompression in persistent biliary
pancreatitis [60,61], type of nutrition [62], role of octreo-
tide, and probiotic prophylaxis. The use of prophylactic
antibiotics has been evaluated in numerous underpow-
ered prospective randomized trials and meta-analyses
[63-66]. These 7 RCTs are best summarized by stating
that there is no good evidence to support the routine
use of prophylactic antibiotics in patients with SAP
[67,68]. Furthermore, the general recommendation is to
stop all antibiotics if they have been previously started in
this scenario.
The optimal type of nutrition (enteral vs. parenteral)
has also been evaluated in multiple prospective random-
ized trials. A systematic review that included 348 pa-
tients from 8 trials showed that enteral nutrition
decreased the risk of death (OR 0.50, 95% CI 0.28 to
0.91), multiple organ failure (OR 0.55, 95% CI 0.37 to
0.81), systemic infection (OR 0.39, 95% CI 0.23 to 0.65),
operative interventions (OR 0.44, 95% CI 0.29 to 0.67),
local septic complications (OR 0.74, 95% CI 0.40 to 1.35)
and length of hospital stay (reduced by 2.4 days) [69].
More importantly, in patients with SAP, enteral nutrition
decreased the risk of death (RR = 0.18, 95% CI 0.06 to
0.58) and multiple organ failure (RR = 0.46, 95% CI 0.16
to 1.29), suggesting that patients should receive enteral
over parenteral nutrition [69]. In many patients, regard-
less of the extent of necrosis on CT, oral ingestion of a
regular diet is well tolerated. If this fails, progression to
nasogastric followed by nasojejunal tube feeding as
needed is recommended.
The role of early ERCP in the context of choledocholi-
thiasis has also been evaluated in prospective studies[61,70-74]. Amongst 153 patients in a multicenter pro-
spective study, patients were divided into 2 groups (with
and without signs of cholestasis) [75]. Although ERCP
was associated with fewer complications than the obser-
vation group (25% vs. 54%, p = 0.02) in patients with
signs of cholestasis, mortality was not significantly lower
(6% vs. 15%, p = 0.2). Additionally, ERCP neither reduced
complications (45% vs. 41%, p = 0.8) nor mortality (14%
vs. 17%, P = 0.7) in patients without cholestasis, suggest-
ing that ERCP should be indicated only in selected pa-
tients with persistent cholestasis [61,74].
Finally, trials evaluating probiotic use reported that
prophylaxis did not reduce the risk of infectious compli-
cations, but actually increased the risk of mortality in
patients with predicted SAP [76]. Similarly, another trial
of 302 patients with moderate to SAP who received ei-
ther octreotide or placebo had similar rates of mortality,
complications, duration of pain, surgical interventions,
and length of hospital stay. This finding suggests that
octreotide should not be used in SAP [77].
Non-traumatic injuries
Iatrogenic bile duct injuries (BDI)
BDIs can be physically and psychologically challenging
errors for both the injurious surgeon, as well as their
colleague asked to repair the injury [78]. Although a de-
tailed description of BDIs and their reconstructions is
beyond the scope of this review, it is important to con-
sider this diagnosis, as the ACS surgeon is often called
as the initial consultant by a surgeon in need. Based on
large population studies, the rate of BDIs approaches
0.4% using laparoscopic techniques and 0.1% with open
approaches [79]. Most BDIs are not recognized intraop-
eratively and instead patients return to the hospital with
complaints of nausea, vomiting, abdominal discomfort
and potentially obstructive biliary symptoms [80]. The
ACS surgeon must hold diagnoses of a BDI and/or
biloma high in their differential diagnosis when assessing
these postoperative patients. Intraoperative diagnoses of
BDIs should be suspected in cases of extensive inflam-
mation, severely contracted gallbladders, unexpected
bleeding that requires multiple clips for control, abnor-
mal anatomy, bile within the operative field, or difficultly
in defining the triangle of Calot, sulcus of Rouvier, me-
dian umbilical fissure, hepatic artery and critical view of
safety [81]. If an injury is suspected, but not clearly evi-
dent, an intraoperative cholangiogram should be per-
formed to evaluate the biliary tree as a first assessment
[82]. Given the tremendous frequency of general sur-
geons to misinterpret intraoperative cholangiograms
however, more than one surgeon with experience and/or
a radiologist is ideal. If doubt persists, consultation with
an HPB surgeon experienced in BDI reconstruction
prior to conversion to an open procedure is highly
Butte et al. World Journal of Emergency Surgery  (2015) 10:13 Page 8 of 10recommended. The status of the right hepatic artery
(90%) in addition to the proximity of the injury and the
quality/loss of ductal tissue will define recommendations
from the referral surgeon [83]. If the surgical team does
not have the expertise to repair the bile duct, 2 closed
suction drains should be placed within the gallbladder
fossa to manage a potential bile leak, followed by imme-
diate referral and/or transfer. Intentional occlusion (clip
or tie) of a transected common bile duct during the
index operation is not helpful due to a lack of subse-
quent proximal dilation, as well as necrosis of the duct
leading to a more proximal injury.
Delayed presentation of a BDI should be suspected by
the ACS in patients who present with nausea, vomiting,
fever and persistent abdominal pain that does not de-
crease with regular analgesics. Liver function tests may
be abnormally elevated not only due to obstruction, but
also because of a biloma. Patients should be studied im-
mediately with an abdominal US and/or CT to define
the presence of collections or abnormal free fluid. It is
important to note that the absence of fluid does not ex-
clude the occurrence of a BDI. Any fluid collection
should be drained with a percutaneous approach. The
biliary tree, and specifically the level of injury, may then
be defined with an MRC and/or ERCP [84,85]. In sce-
narios where the posterior sector has been isolated or
there has been a complete common ductal transection,
retrograde drain cholangiograms and percutaneous
transhepatic cholangiograms (and catheters) are required
respectively [86].
It should be noted that in all BDI patients, the cause
of sepsis may be multifold: [1] intraabdominal collec-
tions/biloma (usually related to the gallbladder bed), [2]
biliperitoneum, [3] cholangitis (when the bile duct has
been completely transected and clipped), and [4] liver
necrosis/failure when the BDI is associated with a vascu-
lar injury [87]. Since the specific cause of sepsis is usu-
ally unknown at the time of presentation, all critically ill
patients should receive immediate fluid resuscitation
and antibiotics. A CT scan should be obtained to assess
the etiology of sepsis. Blood and intraabdominal cultures
are mandatory to guide the therapy.
Duodenal perforation following ERCP
ERCP is a diagnostic and therapeutic procedure that is
employed in a wide range of benign and malignant dis-
eases. It has been described that approximately 10% to
15% of patients sustain procedural complications. Al-
though pancreatitis remains the most common, duo-
denal perforations occur in approximately 1% of patients
[88-90]. Unfortunately the mortality associated with
these perforations is as high as 20% depending on the
series [88]. Treatment depends entirely on patient clin-
ical presentation, location of the perforation, and theinitial indication for the ERCP [91,92]. Injuries are clas-
sified as type I (created in the lateral wall of duodenum
or jejunum during the ERCP scope’s “long view”) or type
II (small perforations of the ampulla of Vater including
the periampullary tissues) [93]. Unlike BDIs during lap-
aroscopic cholecystectomy, most cases (74%) of ERCP
perforations are detected during the ERCP itself [94].
The majority of type I injuries (81%) require surgical
management (duodenal wall repair and periduodenal
drainage with occasional Roux-en-Y duodenojejunost-
omy), whereas most type II (97%) injuries are treated
conservatively (antibiotic therapy and drainage of retro-
peritoneal collections). It should be noted however that
failure of medical management (including percutaneous
drainage) is typical in scenarios of significant retroperi-
toneal fluid [95]. In contrast, patients with significant
retroperitoneal air and very little fluid often recover well
with nonoperative therapies (antibiotics, NPO).
In conclusion, HPB emergencies for the ACS surgeon
are broad in nature and presentation. Although the ap-
propriate treatments can be complex and require multi-
modality care, they are each approached similarly in the
acute phase. This initial assessment involves both diag-
nosis, as well as treatment with resuscitation, antimicro-
bial therapy and multidisciplinary input. By approaching
HPB emergencies in this manner, the ACS surgeon will
be well equipped to deal with all patients.
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